Dual targeting of protein degradation pathways with the selective HDAC6 inhibitor, ACY-1215, and bortezomib is synergistic in lymphoma
Amengual, J. E., Johannet, P. M., Lombardo, M., Zullo, K. M., Hoehn, D., Bhagat, G., Scotto, L., Jirau-Serrano, X., Radeski, D., Heinen, J., Jiang, H., Cremers, S., Zhang, Y., Jones, S. S., O'Connor,Language:
english
Journal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.CCR-14-3068
Date:
June, 2015
File:
PDF, 1.67 MB
english, 2015
File converter
More search results
More benefits 
